PubMed 22962027 TB-4 Phase 1 human safety first-in-human randomized, double-blind, single- and multiple-dose Phase 1 of recombinant human thymosin 4 in healthy volunteers, no serious adverse events: PubMed 34346165
Separation of ingredients suggests an unstable formulation
It is also commonly administered as a push at the end of an IV drip session
Aids immune health and nutrient metabolism
This happens through its ability to inhibit melanin production, which can gradually reduce pigmentation, tanning, and uneven skin tone
This sublingual delivery offers several key advantages: Fast Absorption The peptides enter your bloodstream quickly, often within minutes, so they can start working throughout your body